ARCHIVES

ASCO Urges NCI To Spell Out Metrics of Success Beyond Cutting Groups to Arbitrary Number

This article is from The Cancer Letter archive.

Vol. 37 No. 24 | June 17, 2011

Download PDF Visit The Full Archive

Related Articles

ODAC Recommends Iressa Approval As Third-Line Lung Cancer Treatment

September 27, 2002

Study Links Exercise and Survival In Breast and Colon Cancer Mortality

May 25, 2012

In Brief: NCI Reorganization Announcement Coming Up; No Decisions On Organ Site, Center Programs NCI Reorganization

May 12, 1978

Drug pricing: Amgen’s “bundling” violates antitrust laws, J&J claims in suit.

October 14, 2005

Neutron Clinical Trials Contract Concept Approved

June 22, 1984

In Brief: Kung, Vogt, Hartwell Win general Motors Prizes; Fox Chase Hires Four Scientists; Vitetta Honored

June 14, 1991